SHAREHOLDER ALERT: Pomerantz Law Firm Investigates

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
33
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Yangtze River Port & Logistics Limited - YRIV

NEW YORK, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Yangtze River Port & Logistics Limited (“Yangtze” or the “Company”) (NASDAQ: YRIV). Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Yangtze and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

[Click here to join a class action]

On December 6, 2018, Hindenburg Research (“Hindenburg”) published a report entitled “Yangtze River Port & Logistics: Total Zero.  On-the-Ground Research Shows Assets Appear to be Largely Fabricated”.  The Hindenburg report described Yangtze as “a scheme run by its Chairman & controlling shareholder to siphon money away from U.S. public markets.”  Among other allegations, the Hindenburg report asserted that Yangtze’s “only operating entity has been declared insolvent in China and is involved in multiple undisclosed legal proceedings” and, citing “government-sourced documents and interviews with local officials, we believe that at least 77% of the company’s reported assets are fabricated.” 

Following publication of the Hindenburg Report, Yangtze’s stock price fell $3.34 per share, or 28.74%, over the following two trading sessions, closing at $8.28 per share on December 7, 2018.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com .

CONTACT:

Robert S. Willoughby Pomerantz LLP rswilloughby@pomlaw.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Qifu Technology Transitions to Qfin Holdings and New Strategies

Updated Category News Views 308

Leadership Changes at Qifu Technology Recently, Qifu Technology, Inc. (NASDAQ: QFIN; HKEx: 3660) held its annual general meeting where shareholders adopted key resolutions that will shape the company’s future. One of the notable changes is the rebranding of the company from Qifu Technology, Inc. to Qfin Holdings, Inc. This transition reflects the ambitious growth...

Continue Reading
Luokung's Journey to Nasdaq Compliance and Future Prospects

Updated Category News Views 47

Luokung Completes Compliance with Nasdaq Regulations Luokung Technology Corp. (NASDAQ: LKCO) has exciting news regarding its compliance status with Nasdaq. Recently, the Nasdaq Stock Market notified the company that it has successfully met the minimum bid price requirement. This is a significant development for Luokung, highlighting its positive performance in the stock...

Continue Reading
Qubrid AI Forms Alliance with ASI for Advanced AI Solutions

Updated Category News Views 157

Qubrid AI Partners with ASI for Enhanced Distribution Qubrid AI, a pioneer in enterprise AI technologies, has recently established a distribution agreement with ASI Corporation, a respected technology distributor. This collaboration aims to enhance market access for Qubrid AI's state-of-the-art AI Controller software and high-performance GPU Appliances. Expanding Access...

Continue Reading
Bexion Pharmaceuticals Secures Grant to Propel BXQ-350 Research

Updated Category News Views 198

Bexion Pharmaceuticals Receives Michael J. Fox Foundation Grant Bexion Pharmaceuticals, Inc., a dedicated clinical-stage biopharmaceutical company, has received a substantial grant to support its innovative research initiatives. This grant, awarded by The Michael J. Fox Foundation for Parkinson's Research, amounts to $1.4 million and will specifically fund the preclinical...

Continue Reading
Class Action Alert: Investors of James Hardie Should Act Soon

Updated Category News Views 98

Class Action Alert for James Hardie Industries PLC Investors Attention to all investors of James Hardie Industries PLC (NYSE: JHX)! If you're among those who purchased James Hardie common stock or American Depositary Shares, this is a critical time for you. Recent developments have unveiled a class action lawsuit that demands immediate attention. This action is initiated...

Continue Reading